Research Article
Formulation Development and Evaluation of Nepafenac Novel In Situ Gel
Author(s)
Nalla, A., Panigrahy, R.N., Chinnala, K.M.
Author's Affiliation
Abstract
The aim of present study was to formulate and evaluate Nepafenac liposomal in situ gel. Liposomes were formulated in different ratios using soya lecithin and cholesterol using Rotary Flash Evaporation method. Liposomes were evaluated for drug entrapment efficiency, %entrapment efficiency, particle size analysis, zeta potential and in vitro release studies. Optimized liposomes (F4) were developed into in situ gels. The thermo reversible liposomal in situ gels of Nepafenac were prepared by using poloxamer 407 and with mucoadhesive polymers like HPMC E15 and chitosan. Formulations were sterilized by autoclaving at 121⁰C, at 15 lb pressure for 20 min. The formulations were evaluated for drug content, clarity, pH, gelation temperature, gelation capacity, viscosity, in-vitro drug release studies. Drug and Polymer incompatibilities were evaluated using FTIR spectrophotometer. The drug content of the formulations was in the range 83%-92%. pH of the formulations was in the range 6.43 to 7.42, gelation temperature was in the range 27.5⁰C-40⁰C. In Vitro drug release was in the range of 78%-99% within 12 hours, the extent of gelation and consequently the release of Nepafenac depended on the concentration of polymers used. Nepafenac was released slowly from gels, for a period of 12 hours. Formulation PC5 with poloxamer 407 (18% w/w) and chitosan (0.3% w/w) was found to be suitable as it released 78% of drug for a period of 12 hours. Poloxamer 407/chitosan (PC5) combination was found to have optimum pH and gelation temperature which is required for an in situ gel drug delivery system.
Keywords
In Situ Gel, Liposomes, Entrapment Efficiency, Zeta Potential
Cite This Article
Nalla, A., Panigrahy, R.N., Chinnala, K.M. (2016). Formulation Development and Evaluation of Nepafenac Novel In Situ Gel, International Journal for Pharmaceutical Research Scholars (IJPRS), 5(4), 1-14.